|Bid||76.79 x 100|
|Ask||77.11 x 100|
|Day's Range||77.15 - 78.30|
|52 Week Range||63.68 - 99.14|
|PE Ratio (TTM)||-3.25|
|Dividend & Yield||0.64 (0.81%)|
|1y Target Est||N/A|
A divided federal appeals court on Wednesday upheld the insider trading conviction of Mathew Martoma, a former portfolio manager for billionaire Steven A. Cohen's SAC Capital Advisors LP, after the U.S. Supreme Court made such cases easier to pursue. The 2nd U.S. Circuit Court of Appeals in Manhattan found "overwhelming" evidence that a Michigan doctor received financial benefits from providing confidential information to Martoma about a 2008 Alzheimer's drug trial.
Perrigo (PRGO) gains an FDA consent for the OTC version of AstraZeneca's Nexium post the ongoing patent lawsuit settlement through an agreement.
Perrigo (PRGO) got a big lift off last week’s second quarter financial results. The stock price had a 16% one-day surge after the drug maker posted quarterly financial results that beat estimates and raised its guidance. It offered a stark contradiction to other specialty drug makers, namely the dismal results posted earlier this month by Teva Pharmaceutical Industries (TEVA).